Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors

A Trabalza, C Georgiadis, I Eleftheriadou, J N Hislop, S M Ellison, M E Karavassilis, N D Mazarakis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We have produced high-titre HIV-1 green fluorescent protein-expressing lentiviral (LV) vectors pseudotyped with strain 3908 Venezuelan equine encephalitis virus glycoprotein (VEEV-G) and used them to study transduction of: (1) rat embryonic motor neuron (MN) and striatal neuron primary cultures, (2) differentiated MN cell line NSC-34 and (3) adult rat striatum. In primary neuronal cultures, transduction with VEEV-G-pseudotyped LV was more efficient and more neuronal than with vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped LV. In NSC-34 cells clear retrograde transport of VEEV-G vector particles was observed. In the striatum at the injection site, transduction with the VEEV-G vectors driven by cytomegalovirus or phosphoglycerate kinase promoters exhibited a distinct neuronal tropism with no microglial and only a minor astroglial component, superior to that obtained with VSV-G-pseudotyped LV, irrespective of the promoter used. Neuronal transduction efficiency increased over time. Distal to the injection site transduction of mitral cells in the olfactory bulb, thalamic neurons and dopaminergic neurons in the substantia nigra pars compacta was detected. This, together with observations of retrograde axonal trafficking in vitro indicates that these vectors also possess low level of retrograde neuronal transduction capability in vivo. In this study, we demonstrate both strong neurotropism as well as sustainability of expression and minimal host immune response in vivo, making the VEEV-G-pseudotyped LV vectors potentially useful for gene therapy of neurodegenerative diseases.
Original languageEnglish
Pages (from-to)723-732
Number of pages10
JournalGene Therapy
Volume20
Issue number7
Early online date22 Dec 2012
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Venezuelan Equine Encephalitis Viruses
Glycoproteins
Vesicular Stomatitis
Motor Neurons
Phosphoglycerate Kinase
Viruses
Neurons
Corpus Striatum
Injections
Tropism
Olfactory Bulb
Dopaminergic Neurons
Green Fluorescent Proteins
Cytomegalovirus
Neurodegenerative Diseases
Genetic Therapy
HIV-1
Cell Line

Keywords

  • animals
  • cells, cultured
  • corpus striatum
  • encephalitis virus, Venezuelan equine
  • genetic vectors
  • glycoproteins
  • green fluorescent proteins
  • HIV-1
  • humans
  • lentivirus
  • motor neurons
  • neurodegenerative diseases
  • rats
  • transduction, genetic

Cite this

Trabalza, A., Georgiadis, C., Eleftheriadou, I., Hislop, J. N., Ellison, S. M., Karavassilis, M. E., & Mazarakis, N. D. (2013). Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors. Gene Therapy, 20(7), 723-732. https://doi.org/10.1038/gt.2012.85

Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors. / Trabalza, A; Georgiadis, C; Eleftheriadou, I; Hislop, J N; Ellison, S M; Karavassilis, M E; Mazarakis, N D.

In: Gene Therapy, Vol. 20, No. 7, 07.2013, p. 723-732.

Research output: Contribution to journalArticle

Trabalza, A, Georgiadis, C, Eleftheriadou, I, Hislop, JN, Ellison, SM, Karavassilis, ME & Mazarakis, ND 2013, 'Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors', Gene Therapy, vol. 20, no. 7, pp. 723-732. https://doi.org/10.1038/gt.2012.85
Trabalza, A ; Georgiadis, C ; Eleftheriadou, I ; Hislop, J N ; Ellison, S M ; Karavassilis, M E ; Mazarakis, N D. / Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors. In: Gene Therapy. 2013 ; Vol. 20, No. 7. pp. 723-732.
@article{25d72149444545148510cbf554ee23d7,
title = "Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors",
abstract = "We have produced high-titre HIV-1 green fluorescent protein-expressing lentiviral (LV) vectors pseudotyped with strain 3908 Venezuelan equine encephalitis virus glycoprotein (VEEV-G) and used them to study transduction of: (1) rat embryonic motor neuron (MN) and striatal neuron primary cultures, (2) differentiated MN cell line NSC-34 and (3) adult rat striatum. In primary neuronal cultures, transduction with VEEV-G-pseudotyped LV was more efficient and more neuronal than with vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped LV. In NSC-34 cells clear retrograde transport of VEEV-G vector particles was observed. In the striatum at the injection site, transduction with the VEEV-G vectors driven by cytomegalovirus or phosphoglycerate kinase promoters exhibited a distinct neuronal tropism with no microglial and only a minor astroglial component, superior to that obtained with VSV-G-pseudotyped LV, irrespective of the promoter used. Neuronal transduction efficiency increased over time. Distal to the injection site transduction of mitral cells in the olfactory bulb, thalamic neurons and dopaminergic neurons in the substantia nigra pars compacta was detected. This, together with observations of retrograde axonal trafficking in vitro indicates that these vectors also possess low level of retrograde neuronal transduction capability in vivo. In this study, we demonstrate both strong neurotropism as well as sustainability of expression and minimal host immune response in vivo, making the VEEV-G-pseudotyped LV vectors potentially useful for gene therapy of neurodegenerative diseases.",
keywords = "animals, cells, cultured, corpus striatum, encephalitis virus, Venezuelan equine, genetic vectors, glycoproteins, green fluorescent proteins, HIV-1, humans, lentivirus, motor neurons, neurodegenerative diseases, rats, transduction, genetic",
author = "A Trabalza and C Georgiadis and I Eleftheriadou and Hislop, {J N} and Ellison, {S M} and Karavassilis, {M E} and Mazarakis, {N D}",
year = "2013",
month = "7",
doi = "10.1038/gt.2012.85",
language = "English",
volume = "20",
pages = "723--732",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors

AU - Trabalza, A

AU - Georgiadis, C

AU - Eleftheriadou, I

AU - Hislop, J N

AU - Ellison, S M

AU - Karavassilis, M E

AU - Mazarakis, N D

PY - 2013/7

Y1 - 2013/7

N2 - We have produced high-titre HIV-1 green fluorescent protein-expressing lentiviral (LV) vectors pseudotyped with strain 3908 Venezuelan equine encephalitis virus glycoprotein (VEEV-G) and used them to study transduction of: (1) rat embryonic motor neuron (MN) and striatal neuron primary cultures, (2) differentiated MN cell line NSC-34 and (3) adult rat striatum. In primary neuronal cultures, transduction with VEEV-G-pseudotyped LV was more efficient and more neuronal than with vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped LV. In NSC-34 cells clear retrograde transport of VEEV-G vector particles was observed. In the striatum at the injection site, transduction with the VEEV-G vectors driven by cytomegalovirus or phosphoglycerate kinase promoters exhibited a distinct neuronal tropism with no microglial and only a minor astroglial component, superior to that obtained with VSV-G-pseudotyped LV, irrespective of the promoter used. Neuronal transduction efficiency increased over time. Distal to the injection site transduction of mitral cells in the olfactory bulb, thalamic neurons and dopaminergic neurons in the substantia nigra pars compacta was detected. This, together with observations of retrograde axonal trafficking in vitro indicates that these vectors also possess low level of retrograde neuronal transduction capability in vivo. In this study, we demonstrate both strong neurotropism as well as sustainability of expression and minimal host immune response in vivo, making the VEEV-G-pseudotyped LV vectors potentially useful for gene therapy of neurodegenerative diseases.

AB - We have produced high-titre HIV-1 green fluorescent protein-expressing lentiviral (LV) vectors pseudotyped with strain 3908 Venezuelan equine encephalitis virus glycoprotein (VEEV-G) and used them to study transduction of: (1) rat embryonic motor neuron (MN) and striatal neuron primary cultures, (2) differentiated MN cell line NSC-34 and (3) adult rat striatum. In primary neuronal cultures, transduction with VEEV-G-pseudotyped LV was more efficient and more neuronal than with vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped LV. In NSC-34 cells clear retrograde transport of VEEV-G vector particles was observed. In the striatum at the injection site, transduction with the VEEV-G vectors driven by cytomegalovirus or phosphoglycerate kinase promoters exhibited a distinct neuronal tropism with no microglial and only a minor astroglial component, superior to that obtained with VSV-G-pseudotyped LV, irrespective of the promoter used. Neuronal transduction efficiency increased over time. Distal to the injection site transduction of mitral cells in the olfactory bulb, thalamic neurons and dopaminergic neurons in the substantia nigra pars compacta was detected. This, together with observations of retrograde axonal trafficking in vitro indicates that these vectors also possess low level of retrograde neuronal transduction capability in vivo. In this study, we demonstrate both strong neurotropism as well as sustainability of expression and minimal host immune response in vivo, making the VEEV-G-pseudotyped LV vectors potentially useful for gene therapy of neurodegenerative diseases.

KW - animals

KW - cells, cultured

KW - corpus striatum

KW - encephalitis virus, Venezuelan equine

KW - genetic vectors

KW - glycoproteins

KW - green fluorescent proteins

KW - HIV-1

KW - humans

KW - lentivirus

KW - motor neurons

KW - neurodegenerative diseases

KW - rats

KW - transduction, genetic

U2 - 10.1038/gt.2012.85

DO - 10.1038/gt.2012.85

M3 - Article

VL - 20

SP - 723

EP - 732

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 7

ER -